Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial.
about
Aminoadamantanes for chronic hepatitis CAmantadine therapy for chronic hepatitis CRandomised, double blind, placebo controlled trial of interferon, ribavirin, and amantadine versus interferon, ribavirin, and placebo in treatment naïve patients with chronic hepatitis CViral Determinants of Resistance to Treatment in Patients with Hepatitis CThe p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequencesIdentification of the membrane-active regions of hepatitis C virus p7 protein: biophysical characterization of the loop region.Treatment of hepatitis C virus infectionThe lipophilic bullet hits the targets: medicinal chemistry of adamantane derivativesEffect of interferon and ribavirin combined with amantadine in interferon and ribavirin non-responder patients with chronic hepatitis C (genotype 1).Recent developments in target identification against hepatitis C virus.Association of serum gamma-glutamyl transferase with treatment outcome in chronic hepatitis B patients.Amantadine in treatment of chronic hepatitis C virus infection?Treating viral hepatitis C: efficacy, side effects, and complications.Distribution and dynamics of adamantanes in a lipid bilayerA randomized controlled trial of double versus triple therapy with amantadine for genotype 1 chronic hepatitis C in Latino patientsResponse of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection.A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection.Amantadine therapy for chronic hepatitis C: a dose escalation study.Apoptotic cytokeratin 18 neoepitopes in serum of patients with chronic hepatitis C.Kinetics of soluble tumour necrosis factor (TNF)-alpha receptors and cytokines in the early phase of treatment for chronic hepatitis C: comparison between interferon (IFN)-alpha alone, IFN-alpha plus amantadine or plus ribavirin.Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C.Triple therapy of initial high-dose interferon with ribavirin and amantadine for patients with chronic hepatitis C.A randomized trial of pegylated-interferon-alpha2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin.Retreatment of patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy with daily interferon plus ribavirin plus amantadine.
P2860
Q24194770-D7204C10-D690-45CB-BBF7-4BE3281D22DAQ27473307-B52A8C4C-1AD3-4257-832F-86E563E470C9Q27477967-91081E0C-3387-420C-BBB1-4A0530998D77Q27478062-7BCA9699-26D4-48C3-876C-AE82FF72F86CQ27481676-62072E1C-3D16-4970-8B6F-84B63E693372Q33314995-4547C99D-A196-425B-9FA7-84A20C0B9726Q34099424-0567C99B-D442-46EF-9513-5E3C99D807A0Q34329204-43AA4315-CB56-41A1-9443-042202C23F64Q34605831-B4362FA8-0479-46E7-BF63-B1CF2DF887BFQ35842500-20B589A3-23A7-499B-8337-6B9280DB2FA4Q36050504-6019B890-0C92-4E68-9272-79CD26FDC427Q36234125-29D75420-3A00-4C33-9C60-2CDF5E459EDAQ36564615-165469BB-EFCC-468F-B813-9871F9C80DD4Q37008274-9874A4D7-0F78-4165-A6CB-408E98195AD4Q37105582-9123AB91-FAC2-4A32-A52C-F8D671818D93Q38990471-FB372FE0-3C08-4B97-9AD9-07F5ABCFF0A6Q41603994-C809F1F0-5AFC-422A-A465-1722BB1CBB31Q42992074-444A4632-BFA5-47B2-B304-54000DA973FCQ44801102-1E05B07F-1BDF-48BB-A759-45F8F49A91E8Q44924004-89C020B7-2AFE-4D43-A080-4CA0A2622AC6Q46454514-82A6C586-E50A-4AA3-BCB8-30070485077DQ47594322-8215178F-4A21-478B-B990-24E8771CF19BQ50568686-7CB8078C-838D-49BA-8BA4-8EE472527FCEQ50571978-5ED6C495-86FF-4997-9C8E-B1D26653EA8CQ50575342-4D24B33E-E0EB-4721-94BD-29AF99F2381CQ50580456-73CDB96F-FF4C-4456-8C06-6E471459A25E
P2860
Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Triple therapy with amantadine ...... C: a placebo-controlled trial.
@en
type
label
Triple therapy with amantadine ...... C: a placebo-controlled trial.
@en
prefLabel
Triple therapy with amantadine ...... C: a placebo-controlled trial.
@en
P2093
P356
P1433
P1476
Triple therapy with amantadine ...... C: a placebo-controlled trial.
@en
P2093
Bernd Kronenberger
Eva Herrmann
Gerd R Pape
Holger Hinrichsen
Karsten Wursthorn
Peter Buggisch
Samer Nasser
Thomas Berg
Tilman Gerlach
Tobias Goeser
P304
P356
10.1053/JHEP.2003.50219
P407
P577
2003-06-01T00:00:00Z